Northland Capital Partners Limited Morning Report

W RESOURCES (WRES.L) | SALVARX GROUP (SALV.L) | MANAGEMENT RESOURCE SOLUTIONS (MRS.L) | EDENVILLE ENERGY (EDL.L)

Northland Capital Partners Limited Morning Report

SALVARX (SALV.L) | EQTEC (EQT.L) | FISHING REPUBLIC (FISH.L) | CLONTARF ENERGY (CLON.L) | ARIAN SILVER CORPORATION (AGQ.L)

Northland Capital Partners Limited Morning Report

MOTIF BIO (MTFB.L) | SALVARX GROUP (SALV.L) | PREMIER AFRICAN MINERALS (PREM.L) | EDENVILLE ENERGY (EDL.L)

Northland Capital Partners Limited Morning Report

KERAS RESOURCES (KRS.L) | SALVARX GROUP (SALV.L) | CONNEMARA MINING COMPANY (CON.L)

Northland Capital Partners Limited Morning Report

VELTYCO GROUP (VLTY.L) | PREMIER AFRICAN MINERALS (PREM.L) | SALVARX GROUP (SALV.L) | TECHFINANCIALS (TECH.L)

Northland Capital Partners Morning Report

SALVARX (SALV.L) | VENTURE LIFE GROUP (VLG.L)

Northland Capital Partners Morning Report

SalvaRx’s pipeline continues to expand. Through two recent investments, the group now has exposure to four immuno-oncology portfolio companies. Moreover, the group’s pipeline continues to progress. Notably, we expect portfolio company Intensity Therapeutics to soon dose its first ever patient, which would represent a major milestone for the business.

Northland Capital Partners Morning Report

SalvaRx (SALV.L) – BUY*: Intensity Therapeutics reported positive results

Small Cap Breakfast

Ergomed ( ERGO. L ) | PipeHawk (PIP.L) | CAP-XX (CPX.L) | Focusrite (TUNE.L) | Maintel Holdings (MAI.L) | Learning Technologies Group (LTG.L) | SalvaRx Group (SALV.L) | Tiso Blackstar Group (TBGR.L) | Photonstar LED Group (PSL.L) | Michelmersh Brick Holdings (MBH.L)

Northland Capital Partners Morning Report

ImmuPharma plc (IMM.L) – BUY*: L&G increases its holding | SalvaRx (SALV.L) – BUY*: New investment

Northland Capital Partners Morning Report

Savannah Resources (SAV.L) – CORP: Subscription update | SalvaRx (SALV.L) – BUY*: Update | TechFinancials (TECH.L) – DIVIDEND | Sunrise Resources (SRES.L) – CORP: CS Project update

Northland Capital Partners Morning Report

Premier African Minerals (PREM.L) – CORP: RHA update | Savannah Resources (SAV.L) – CORP: Oman and Mozambique updates | SalvaRx (SALV.L) – BUY*: New investment

Diversifying portfolio spreads the risk

SalvaRx's (SALV) long term aim is to develop a pipeline of complementary cancer immunotherapy-focused products and technologies, activating the body's immune system to down-regulate tumour progression. Achieving a durable patient response to support long-term survival is essential for Pharma companies scouting new clinical assets. SALV's expanding product portfolio continues to create a substantial licensing or exit opportunity for investors.

Northland Capital Partners Morning Report

Churchill Mining (CHL.L) – SPECULATIVE BUY*: ICSID Arbitration update | SalvaRx Group (SALV.L) – CORP: Interim results | ValiRx (VAL.L) – CORP: Update | PhotonStar (PSL.L) – BUY*: Working Capital facility | Rockwell Diamonds (RDI.L) – CORP: Board and management changes

Northland Capital Partners Morning Report

Premier African Minerals (PREM.L) – CORP: Funding and projects update | SalvaRx (SALV.L) – BUY*: Business update

Warpaint London+ (W7L, House Stock at 375p) - Trading ahead of expectations - +10% upgrade implied

The Hardman & Co Monthly: April 2024

Feature article: Steady as she goes, but could be better: A review of investment company liquidity since 2016 Liquidity is the lifeblood of equity markets. The measurement of liquid asset availability to a market or company is a way of gauging a market’s health. This article builds on our previous work, which analysed the liquidity data for non-financial trading companies, by applying the same analytical techniques to the investment companies (IC) space. We analyse liquidity for ICs as a whol

Avon Protection - Unmasking its growth potential

Avon Protection’s capital markets day highlighted its continued focus on medium-term margin expansion (targeting operating margin of 14–16%), concentrating on its core business of respirators and head protection. The unwinding of the armour business, alongside the consolidation of Team Wendy (acquired in H220) should enable Avon to benefit from rising global defence spending. Its strong relationship with the US DoD, and organic growth opportunities with recurring revenue from necessary product r

Hybridan Small Cap Feast - 15 April 24

15th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Change of Market: TheWorks (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated propositio

Morning Note – 9 April 2024

Morning Note – 8 April 2024

Hybridan Small Cap Feast - 17 April 24

17th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radi

Hardman & Co Research: Tissue Regenix (TRX) - Six consecutive periods of >20% growth

TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023. Further growth in 202

Cambridge Nutritional Sciences - H1 2024 interims: Executing a newly focussed st

Cambridge Nutritional Sciences (CNS) has published its H1 2024 results to end September 2023. Group revenues grew 44% to £4.9m and gross profits increased by 63% to £3.1m, with the company benefitting from newfound operational efficiencies. With its now streamlined strategy focussing on the core Health & Nutrition business and the initial signs of an encouraging uptick in sales momentum, we believe the company is well positioned for growth that will help create future value for shareholders. We

Venture Life Group - Strong organic growth; focus on EBITDA

Venture Life has reported FY23 results to December 2023, following the February trading update. Revenues grew 17% in the year to £51.4m (our est. £50.7m) and adjusted EBITDA was £11.6m (our est. £11.6m). Cash conversion was 85%, generating £9.8m of cash from operations. Cash generation and no M&A in 2023 allowed the company to de-lever, closing FY23 with net debt to adjusted EBITDA at 1.3x. Management have focused on growth with three therapy areas generating double-digit revenue growth and onli

Morning Note – 22 March 2024

Hardman & Co Healthcare Index: 2023 – Capital demands dent performance

The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (

Diaceutics | FY23 update – 22% revenue growth, £16.7m YE cash

Diaceutics has released a trading statement for the year to December 2023 guiding to revenue growth of 22% YoY to £23.7m, up 19% on a constant currency basis. The order book jumped 57% to £26.6m, of which c£12.3m is expected to be realised in FY24, and which currently stands at £30.8m. The proportion of recurring revenue continues to increase and is now over 50% (FY22 35%). Cash at YE23 stood at £16.7m, indicating a near halving of the rate of cash burn in 2H23 compared to 1H23. We adjust our FY

Zoetis Inc.: Launch Of CircoMatch & Other Drivers, Financial Forecasts, DCF & Comparables Valuation, ESG & Other Risks (02/23)

Zoetis delivered a decent set of results for the last quarter of 2022 meeting analyst expectations as well as the high end of its management guidance. Despite the economic challenges, ongoing pandemic recovery, and the political unpredictability brought on by the war in Ukraine, they delivered operational growth for the year in each of their top 13 markets. The company's unique companion animal portfolio drove its 8% operational revenue increase for the year, growing 14% operationally. In compar

Morning Note – 12 February 2024